Developer docs
API playgroundTry for free, no card

Search company profiles

Remedy Robotics

Full company profile

uuid0003xht

Namestring
Remedy Robotics
Legal namestring
Remedy Robotics Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Remedy Robotics is a San Francisco-based medical technology company developing the N1 System, an endovascular surgical robotics platform designed to perform neurointerventional and cardiovascular procedures with onsite, remote, or autonomous control. The system integrates proprietary custom-built catheters with AI-enabled software and machine-learning models that handle perception, planning, and control across the procedure — from femoral access through catheter navigation (e.g., to the M2 segment) to withdrawal — supporting independent control of up to five tools, contrast injection, and audiovisual communication, plus a remote Operator Console that lets clinicians drive the robot over standard internet connectivity. Founded in 2020–2022 by David Bell (CEO) and Jake Sganga (CTO), Remedy has progressed from first remote drive demonstrations (2021) through remote invivo animal work (Jan 2022), autonomous vascular-model navigation (Jan 2022), UCLA hospital integration (Dec 2023), first-in-human robotic neurointervention at Unity Health Toronto (Nov 2024), and the world's first fully remote human neurointerventional procedures (Oct 2025). The company targets hospitals and healthcare systems as enterprise customers, with planned FDA IDE submission, TGA approval in Australia, and a razor-and-blade-plus-software commercial model across N1 hardware, proprietary single-use catheters, and software/SaaS services.

Short descriptiontext

Remedy Robotics builds the N1 System, an endovascular surgical robotics platform with custom catheters and AI-enabled software that lets clinicians perform stroke and cardiovascular interventions onsite, remotely, or autonomously. It targets hospitals and health systems worldwide via clinical trials and partnerships with stroke networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endovascular robotics, surgical robotics platform, remote telerobotic surgery, neurointerventional systems, stroke thrombectomy devices
Industry2 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code4 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Endovascular Surgical Robotics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1N1 System (Robotic Hardware)
TypeHardware Sales
Description

Sale or lease of the Remedy N1 robotic system to hospitals and healthcare facilities. The system is currently under development and not yet approved for sale.

remedyrobotics.com
2Single-Use Catheters and Disposables
TypeHardware Sales
Description

Consumable revenue from proprietary catheters used during procedures. The company has custom-built catheters as part of its proprietary hardware.

remedyrobotics.com
3Software/SaaS Services
TypeSubscription Recurring
Description

Software-enabled services potentially including per-procedure fees, subscription models for remote control software, and AI-enabled planning and visualization tools.

remedyrobotics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Remedy Robotics develops the N1 System, an endovascular surgical robot that performs entire thrombectomy and neurointerventional procedures with onsite, remote, or autonomous control. The platform combines custom-built catheters with AI-enabled software and machine learning, enabling clinicians to deliver endovascular intervention for stroke and cardiovascular emergencies without geographic barriers. The system is currently in clinical development and not yet commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 97% of stroke patients across the world do not have access to life-saving endovascular thrombectomy
+3 more records
Product overview1 text field

Remedy Robotics offers the N1 System - the world's first endovascular robot that performs entire procedures with onsite, remote, or autonomous control. The system combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver flawless, immediate endovascular intervention for stroke and cardiovascular emergencies. The portfolio includes the core N1 robotic platform, custom-built catheters designed specifically for robotic procedures, and an Operator Console that enables clinicians to drive the robot remotely from anywhere. The system is under development and not yet available for sale.

Product and service3 records
1Remedy N1 System
CategoryEndovascular Surgical Robotics Platform
Description

Endovascular surgical robot that performs entire procedures with onsite, remote, or autonomous control. Combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver endovascular intervention for stroke and cardiovascular emergencies. Designed for hospitals and healthcare systems serving stroke and neurovascular patients, including those in geographic regions without local specialist interventionists.

2Remedy Custom-Built Catheters
CategoryRobotic Endovascular Catheters (Consumables)
Description

Proprietary single-use catheters custom-built for the N1 System, designed specifically for robotic endovascular procedures. Consumable component used per procedure and sold alongside the system to hospitals and healthcare facilities.

3Remedy Operator Console
CategoryRobotic Surgical Control Console
Description

Surgical user interface through which clinicians drive the N1 System remotely. Enables operators to perform telerobotic endovascular interventions from any location with internet connectivity, including from a separate hospital than the patient.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Mission Thrombectomy
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Remedy Robotics was chosen as the exclusive robotics partner by Mission Thrombectomy to expand access to thrombectomy treatment for stroke patients using Remedy's N1 System. The partnership aims to leverage telerobotic technology to improve global access to endovascular thrombectomy, especially in underserved regions. Mission Thrombectomy has been at the forefront of accelerating access to endovascular thrombectomy since 2016, with regional committees in over 100 countries.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-13
Description

Strategic partnership with the Australian Stroke Alliance (representing 40 different health bodies) to expand access to endovascular thrombectomy in Australia. Remedy will collaborate with the alliance to gain regulatory approval and deploy its remotely operated robotic system across hospitals to improve stroke care, especially in rural and remote areas. The partnership aims to conduct remote stroke treatment trials in Darwin and Alice Springs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

Hospital integration and connectivity study conducted at UCLA, with results published in the American Journal of Neuroradiology. The study demonstrated successful integration of the robot into a clinical environment with remote operation by clinicians from multiple locations up to 2,700 miles away.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Clinical partnership with Unity Health Toronto for first-in-human procedures (November-December 2024) and world's first fully remote neurointerventional procedures (October 2025). Dr. Vitor Mendes Pereira and team at Unity Health performed the landmark procedures. The remote procedures were conducted with the surgeon at St. Joseph's Health Centre and patients at St. Michael's Hospital across Toronto.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

First invivo (living) trials completed in January 2022 with expert guidance of the team at Covance in San Mateo. The trial involved swine whose neurovasculature is similar to humans, with simulated procedures completed without damage to vasculature.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with SVIN through Mission Thrombectomy, which is an initiative of SVIN. The broader SVIN network will provide critical input and support for N1 System development. Remedy attended SVIN 2025 Annual Meeting in Orlando.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website, indicating collaboration or clinical interest in the technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital and academic partner on the Remedy Robotics website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

11Austin Health
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

remedyrobotics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a hospital partner on the Remedy Robotics website.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Public surgical robotics company building a single-port robotic system for abdominal procedures. Different indication but comparable business-model risks: pre-revenue, capital-intensive, chasing surgical-robotics adoption in a hospital procurement environment.

TypeBroad incumbent
Description

MicroPort has endovascular and neurovascular device franchises (e.g., APOLLO, WILLIS covered stents) overlapping with Remedy's stroke-treatment customer base. Could add a robotics platform through acquisition or internal development.

TypeEmerging player
Description

French startup developing the R-One robotic platform for coronary and peripheral endovascular interventions. Direct endovascular robotics competitor with overlapping procedural use cases (cardiovascular intervention) but earlier commercial stage and narrower indication focus.

TypeDirect peer
Description

Penumbra's REAL System is the most direct endovascular robotic competitor — also targeting mechanical thrombectomy with a joystick-controlled robot. Closely aligned business model (capital equipment + consumables) and customer base (neurointerventional radiologists and stroke centers).

TypeBroad incumbent
Description

Dominant surgical robotics incumbent (da Vinci) with the Ion platform for catheter-based procedures. Sets the benchmark for hospital robotics adoption and could expand Ion into neurointerventional indications, applying vastly greater resources against Remedy's niche.

TypeEmerging player
Description

Brainlab sells surgical navigation and intra-operative imaging used by neurointerventionalists, overlapping with Remedy's hospital customers. Could partner with or compete against Remedy in the neurointerventional workflow.

TypeBroad incumbent
Description

J&J's Ottava general surgery robot and MONARCH platform for bronchoscopy make it a broad surgical robotics incumbent. Has the resources, regulatory expertise, and global hospital salesforce to enter neurointerventional robotics as the market matures.

TypeBroad incumbent
Description

Medtronic operates in both endovascular intervention (Solitaire stent retriever, cranial robotics) and surgical robotics (Hugo platform). Has the capital, clinical trial infrastructure, and hospital relationships to enter telerobotic neurointervention if the market validates.

TypeEmerging player
Description

Early-stage company developing a catheter-based robotic platform for structural heart and endovascular procedures. Closest emerging-startup analog to Remedy in technology approach and clinical focus on catheter-delivered therapy.

TypeBroad incumbent
Description

Stryker's Neurovascular division dominates mechanical thrombectomy (Trevo devices) and owns Mako surgical robotics. Strong incumbent in both Remedy's adjacent neurovascular device market and the broader surgical robotics space, with far greater capital and distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remedy Robotics

Endovascular Surgical Roboticsremedyrobotics.com

Remedy Robotics builds the N1 System, an endovascular surgical robotics platform with custom catheters and AI-enabled software that lets clinicians perform stroke and cardiovascular interventions onsite, remotely, or autonomously. It targets hospitals and health systems worldwide via clinical trials and partnerships with stroke networks.

What Remedy Robotics does

Remedy Robotics is a San Francisco-based medical technology company developing the N1 System, an endovascular surgical robotics platform designed to perform neurointerventional and cardiovascular procedures with onsite, remote, or autonomous control. The system integrates proprietary custom-built catheters with AI-enabled software and machine-learning models that handle perception, planning, and control across the procedure — from femoral access through catheter navigation (e.g., to the M2 segment) to withdrawal — supporting independent control of up to five tools, contrast injection, and audiovisual communication, plus a remote Operator Console that lets clinicians drive the robot over standard internet connectivity. Founded in 2020–2022 by David Bell (CEO) and Jake Sganga (CTO), Remedy has progressed from first remote drive demonstrations (2021) through remote invivo animal work (Jan 2022), autonomous vascular-model navigation (Jan 2022), UCLA hospital integration (Dec 2023), first-in-human robotic neurointervention at Unity Health Toronto (Nov 2024), and the world's first fully remote human neurointerventional procedures (Oct 2025). The company targets hospitals and healthcare systems as enterprise customers, with planned FDA IDE submission, TGA approval in Australia, and a razor-and-blade-plus-software commercial model across N1 hardware, proprietary single-use catheters, and software/SaaS services.

Remedy Robotics firmographics

Firmographics
Name
Remedy Robotics
Legal name
Remedy Robotics Inc.
Website
https://remedyrobotics.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Remedy Robotics builds the N1 System, an endovascular surgical robotics platform with custom catheters and AI-enabled software that lets clinicians perform stroke and cardiovascular interventions onsite, remotely, or autonomously. It targets hospitals and health systems worldwide via clinical trials and partnerships with stroke networks.
Ownership category
akta.pro rank

Remedy Robotics industry classification

Industry
Product category
Endovascular Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Endovascular robotics
  • Surgical robotics platform
  • Remote telerobotic surgery
  • Neurointerventional systems
  • Stroke thrombectomy devices

Where Remedy Robotics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Remedy Robotics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. N1 System (Robotic Hardware): Sale or lease of the Remedy N1 robotic system to hospitals and healthcare facilities. The system is currently under development and not yet approved for sale.
  2. Single-Use Catheters and Disposables: Consumable revenue from proprietary catheters used during procedures. The company has custom-built catheters as part of its proprietary hardware.
  3. Software/SaaS Services: Software-enabled services potentially including per-procedure fees, subscription models for remote control software, and AI-enabled planning and visualization tools.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Remedy Robotics product offering

Product offering

Core offering

Remedy Robotics develops the N1 System, an endovascular surgical robot that performs entire thrombectomy and neurointerventional procedures with onsite, remote, or autonomous control. The platform combines custom-built catheters with AI-enabled software and machine learning, enabling clinicians to deliver endovascular intervention for stroke and cardiovascular emergencies without geographic barriers. The system is currently in clinical development and not yet commercially available.

Product overview

Remedy Robotics offers the N1 System - the world's first endovascular robot that performs entire procedures with onsite, remote, or autonomous control. The system combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver flawless, immediate endovascular intervention for stroke and cardiovascular emergencies. The portfolio includes the core N1 robotic platform, custom-built catheters designed specifically for robotic procedures, and an Operator Console that enables clinicians to drive the robot remotely from anywhere. The system is under development and not yet available for sale.

Differentiator

Problem solved

Functional benefit

Products and services

  • Remedy N1 System Endovascular surgical robot that performs entire procedures with onsite, remote, or autonomous control. Combines proprietary custom-built catheters with AI-enabled software and machine learning to deliver endovascular intervention for stroke and cardiovascular emergencies. Designed for hospitals and healthcare systems serving stroke and neurovascular patients, including those in geographic regions without local specialist interventionists.
  • Remedy Custom-Built Catheters Proprietary single-use catheters custom-built for the N1 System, designed specifically for robotic endovascular procedures. Consumable component used per procedure and sold alongside the system to hospitals and healthcare facilities.
  • Remedy Operator Console Surgical user interface through which clinicians drive the N1 System remotely. Enables operators to perform telerobotic endovascular interventions from any location with internet connectivity, including from a separate hospital than the patient.

Quantifiable outcome

  • 97% of stroke patients across the world do not have access to life-saving endovascular thrombectomy
  • +3 more outcomes

Companies that use Remedy Robotics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Remedy Robotics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Remedy Robotics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Mission ThrombectomycoreStrategic or Co-development Partner · 27 October 2025Remedy Robotics was chosen as the exclusive robotics partner by Mission Thrombectomy to expand access to thrombectomy treatment for stroke patients using Remedy's N1 System. The partnership aims to leverage telerobotic technology to improve global access to endovascular thrombectomy, especially in underserved regions. Mission Thrombectomy has been at the forefront of accelerating access to endovascular thrombectomy since 2016, with regional committees in over 100 countries.
  • Australian Stroke AlliancecoreStrategic or Co-development Partner · 13 October 2025Strategic partnership with the Australian Stroke Alliance (representing 40 different health bodies) to expand access to endovascular thrombectomy in Australia. Remedy will collaborate with the alliance to gain regulatory approval and deploy its remotely operated robotic system across hospitals to improve stroke care, especially in rural and remote areas. The partnership aims to conduct remote stroke treatment trials in Darwin and Alice Springs.
  • UCLA (University of California, Los Angeles)coreStrategic or Co-development Partner · 25 April 2025Hospital integration and connectivity study conducted at UCLA, with results published in the American Journal of Neuroradiology. The study demonstrated successful integration of the robot into a clinical environment with remote operation by clinicians from multiple locations up to 2,700 miles away.
  • Unity Health TorontocoreStrategic or Co-development Partner · 1 November 2024Clinical partnership with Unity Health Toronto for first-in-human procedures (November-December 2024) and world's first fully remote neurointerventional procedures (October 2025). Dr. Vitor Mendes Pereira and team at Unity Health performed the landmark procedures. The remote procedures were conducted with the surgeon at St. Joseph's Health Centre and patients at St. Michael's Hospital across Toronto.
  • Covance (San Mateo)minorStrategic or Co-development Partner · 1 January 2022First invivo (living) trials completed in January 2022 with expert guidance of the team at Covance in San Mateo. The trial involved swine whose neurovasculature is similar to humans, with simulated procedures completed without damage to vasculature.
  • Society of Vascular and Interventional Neurology (SVIN)coreStrategic or Co-development PartnerPartnership with SVIN through Mission Thrombectomy, which is an initiative of SVIN. The broader SVIN network will provide critical input and support for N1 System development. Remedy attended SVIN 2025 Annual Meeting in Orlando.
  • Mass General BrighamminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website, indicating collaboration or clinical interest in the technology.
  • Barts Health NHSminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • Monash University / Monash HealthminorStrategic or Co-development PartnerListed as a hospital and academic partner on the Remedy Robotics website.
  • Royal Melbourne HospitalminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • Austin HealthminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • National University Hospital Singapore (NUHS)minorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • National University Hospital Sri LankaminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • Gold Coast University HospitalminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.
  • Jikei University HospitalminorStrategic or Co-development PartnerListed as a hospital partner on the Remedy Robotics website.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Remedy Robotics competitors and assessment

Company assessment

Emerging players

  • Vicarious Surgical: Public surgical robotics company building a single-port robotic system for abdominal procedures. Different indication but comparable business-model risks: pre-revenue, capital-intensive, chasing surgical-robotics adoption in a hospital procurement environment.
  • Robocath: French startup developing the R-One robotic platform for coronary and peripheral endovascular interventions. Direct endovascular robotics competitor with overlapping procedural use cases (cardiovascular intervention) but earlier commercial stage and narrower indication focus.
  • Brainlab: Brainlab sells surgical navigation and intra-operative imaging used by neurointerventionalists, overlapping with Remedy's hospital customers. Could partner with or compete against Remedy in the neurointerventional workflow.
  • Capstan Medical: Early-stage company developing a catheter-based robotic platform for structural heart and endovascular procedures. Closest emerging-startup analog to Remedy in technology approach and clinical focus on catheter-delivered therapy.

Broad incumbents

  • MicroPort: MicroPort has endovascular and neurovascular device franchises (e.g., APOLLO, WILLIS covered stents) overlapping with Remedy's stroke-treatment customer base. Could add a robotics platform through acquisition or internal development.
  • Intuitive Surgical: Dominant surgical robotics incumbent (da Vinci) with the Ion platform for catheter-based procedures. Sets the benchmark for hospital robotics adoption and could expand Ion into neurointerventional indications, applying vastly greater resources against Remedy's niche.
  • Johnson & Johnson (MedTech Robotics): J&J's Ottava general surgery robot and MONARCH platform for bronchoscopy make it a broad surgical robotics incumbent. Has the resources, regulatory expertise, and global hospital salesforce to enter neurointerventional robotics as the market matures.
  • Medtronic: Medtronic operates in both endovascular intervention (Solitaire stent retriever, cranial robotics) and surgical robotics (Hugo platform). Has the capital, clinical trial infrastructure, and hospital relationships to enter telerobotic neurointervention if the market validates.
  • Stryker: Stryker's Neurovascular division dominates mechanical thrombectomy (Trevo devices) and owns Mako surgical robotics. Strong incumbent in both Remedy's adjacent neurovascular device market and the broader surgical robotics space, with far greater capital and distribution.

Direct peers

  • Penumbra: Penumbra's REAL System is the most direct endovascular robotic competitor — also targeting mechanical thrombectomy with a joystick-controlled robot. Closely aligned business model (capital equipment + consumables) and customer base (neurointerventional radiologists and stroke centers).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Remedy Robotics social profiles

Digital presence

Remedy Robotics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remedy Robotics leadership team

Management profile

Number of profiles

Profiles4 records

Remedy Robotics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remedy Robotics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remedy Robotics

What does Remedy Robotics do?

Remedy Robotics develops the N1 System, an endovascular surgical robot that performs entire thrombectomy and neurointerventional procedures with onsite, remote, or autonomous control. The platform combines custom-built catheters with AI-enabled software and machine learning, enabling clinicians to deliver endovascular intervention for stroke and cardiovascular emergencies without geographic barriers. The system is currently in clinical development and not yet commercially available.

Is Remedy Robotics a public or private company?

Remedy Robotics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Remedy Robotics founded?

Remedy Robotics was founded in 2022. It employs 11 to 50 people.

Where is Remedy Robotics based?

Remedy Robotics is headquartered in San Francisco, United States, in the North America region.

How does Remedy Robotics make money?

Three revenue lines are on record. N1 System (Robotic Hardware) is the primary driver. The others are single-Use Catheters and Disposables and software/SaaS Services.

Who are Remedy Robotics's main competitors?

Emerging players on record are Vicarious Surgical, Robocath, Brainlab and Capstan Medical. Broad incumbents are MicroPort, Intuitive Surgical, Johnson & Johnson (MedTech Robotics), Medtronic and Stryker. Penumbra is listed as a direct peer.

Does Remedy Robotics have an API?

No public API is recorded for Remedy Robotics.

What industry is Remedy Robotics in?

Remedy Robotics's product category is Endovascular Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedTech DiveRemedy Robotics raises $62M; Capstan’s mitral replacement robot progressesRemedy Robotics raised $62 million in a Series B led by DCVC to support a pivotal trial with UC, aiming for FDA approval of its N1 neurovascular robot. Capstan Medical performed its first U.S. transcatheter mitral valve replacement with its Compass robot on Nov. 9.Startup ResearcherRemedy Robotics Raises US$62 Million Series B RoundRemedy Robotics raised $62 million in Series B funding led by DCVC, with participation from UC Investments, Skip Capital, and Hostplus. The capital will support a pivotal clinical trial with UC and advance FDA approval for its N1 System, which performs endovascular procedures. The company plans to develop full autonomy and prepare for trials across the UC network.Startup DailyExpat's remote surgery medtech scores $92 million Series B for stroke careRemedy Robotics raised $62 million in a Series B led by DCVC, with existing backers and new investors. The funds will support a clinical trial of its N1 remote surgery robot for stroke care, seeking FDA approval. The company also plans to place prototype robots with clinical partners.VentureburnRemedy Robotics Raises $62M to Advance AI Cardiovascular CareRemedy Robotics closed a $62 million Series B led by DCVC on 16 November 2026. The funding will support a landmark clinical trial with the University of California and progress toward FDA approval for its N1 robotic cardiovascular system. The system is not yet approved for clinical use.Pulse 2.0Remedy Robotics Raises $62 Million Series B For Cardiovascular Robotic System DevelopmentRemedy Robotics raised $62 million in Series B funding led by DCVC to advance its AI-enabled endovascular robotic platform toward clinical trials and FDA approval. The capital will support a pivotal trial with the University of California and prototype deployments with partners like SVIN Mission Thrombectomy. The N1 System remains under development and is not available for sale or clinical use.Dealroom.coRemedy Robotics raises $62M to push robotic stroke care remote | Dealroom NewsRemedy Robotics raised $62 million in Series B funding led by DCVC to develop its AI-enabled endovascular surgery platform. The company is finalizing its N1 System, which uses machine learning to analyze imaging and perform procedures remotely. The funds will support a clinical trial with UC and work toward FDA approval.Unite.AIRemedy Robotics Raises $62M Series B to Advance AI Cardiovascular CareRemedy Robotics raised $62 million in Series B funding led by DCVC to advance its AI robotic platform N1 for cardiovascular procedures. The capital will support a pivotal clinical trial with the University of California and prototype deployments across clinical partners. N1 remains under development and is not available for sale or clinical use.Securities.ioRemedy Robotics Raises $62 Million Series B For Planned UC TrialRemedy Robotics raised $62 million in Series B financing led by DCVC to fund a pivotal clinical trial with the University of California and prototype deployments. The company plans to deploy N1 Systems with partners like SVIN Mission Thrombectomy and the Australian Stroke Alliance, while advancing AI and autonomous functions. The device remains investigational and is not available for clinical use.FinSMEsRemedy Robotics Raises $62M in Series B FundingRemedy Robotics raised $62M in Series B funding led by DCVC. The company will use the funds to accelerate a pivotal clinical trial with UC, advance FDA approval for neurovascular intervention, and deploy its N1 robotic system. It partners with over 100 hospitals worldwide.HIT ConsultantRemedy Robotics Raises $62M to Advance Remote Endovascular Stroke Robotics Toward FDA ApprovalRemedy Robotics raised $62M in Series B funding led by DCVC to advance its AI-enabled endovascular robotic platform, the N1 System, toward pivotal clinical trials and FDA approval. Proceeds will fund a planned neurovascular trial with UC and expand prototype deployments. The system uses machine learning for preoperative simulation and real-time image registration.